Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(13):970-973; doi:10.1093/jnci/93.13.970
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Garber, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Garber, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 13, 970-973, July 4, 2001
© 2001 Oxford University Press

NEWS

STI571 Revolution: Can the Newer Targeted Drugs Measure Up?

Ken Garber

Not since the interferon craze of the early 1980s has a cancer drug captured the public imagination like Novartis’s STI571. Under the trade name GleevecTM, it won approval from the U.S. Food and Drug Administration on May 10 for treating chronic myeloid leukemia after a lightning-fast 2 1/2-month review (see sidebar, p. 972).

Network TV special reports and a Time cover story trumpeted the drug. American Society of Clinical Oncology President Larry Norton, M.D., in the New York Times, called STI571 "the beginning of a sea change—and I am speaking conservatively—in the way we practice medicine."

The drug is amazingly effective: In a phase I trial, 98% of patients with chronic myeloid leukemia achieved a complete hematologic response, and phase II results have been almost as stunning. But only about 4,500 people in the United States develop CML each year. The burning question: Will . . . [Full Text of this Article]

Questions Remain


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?